Intraday Movement and Market Context
On 8 December 2025, Concord Biotech’s stock touched an intraday low of Rs 1364, reflecting a decline of 2.85% for the day. This underperformance was sharper than the Pharmaceuticals & Biotechnology sector’s movement, with the stock lagging the sector by 1.84%. The broader market, represented by the Sensex, opened flat but later declined by 353.06 points, or 0.51%, closing at 85,271.78. Despite this, the Sensex remains within 1.04% of its 52-week high of 86,159.02 and is trading above its 50-day moving average, signalling a generally bullish trend for the benchmark index.
Concord Biotech’s share price is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward pressure on the stock over multiple time horizons.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Long-Term Price Performance
Over the past year, Concord Biotech’s stock has recorded a return of -37.21%, a stark contrast to the Sensex’s 4.35% gain during the same period. The stock’s 52-week high was Rs 2451.65, indicating a substantial decline from its peak. This performance places Concord Biotech among the underperformers within the BSE500 index over the last three years, one year, and three months.
Financial Metrics and Profitability Trends
Recent financial data reveals a subdued growth trajectory for Concord Biotech. The company’s operating profit has shown a compound annual rate of change of -0.48% over the last five years, signalling limited expansion in core profitability. The latest quarterly Profit Before Tax (PBT) stood at Rs 72.33 crore, reflecting a decline of 32.1% compared to the previous four-quarter average.
Operating cash flow for the year is reported at Rs 244.52 crore, marking the lowest level in recent periods. Additionally, the Profit After Tax (PAT) for the latest six months is Rs 107.64 crore, which represents a contraction of 30.7%. These figures indicate pressures on the company’s earnings and cash generation capabilities.
Valuation and Efficiency Indicators
Concord Biotech’s return on equity (ROE) is recorded at 17.7%, which is relatively high and suggests efficient utilisation of shareholder funds. However, the stock’s price-to-book value ratio stands at 8, indicating a valuation that is considered expensive relative to book value. Despite this, the stock’s valuation remains broadly in line with historical averages observed among its peers in the Pharmaceuticals & Biotechnology sector.
Debt and Shareholding Structure
The company maintains a low average debt-to-equity ratio, effectively at zero, which points to a conservative capital structure with minimal reliance on external borrowings. Promoters hold the majority shareholding in Concord Biotech, providing a stable ownership base.
Why settle for Concord Biotech ? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sector and Market Comparison
While the Pharmaceuticals & Biotechnology sector has experienced varied performance, Concord Biotech’s stock has notably lagged behind sectoral benchmarks. The Sensex’s current position near its 52-week high and its trading above key moving averages contrasts with Concord Biotech’s downward trend and trading below all major moving averages. This divergence highlights company-specific factors influencing the stock’s trajectory.
Summary of Key Concerns
The stock’s fall to Rs 1364, its lowest level in a year, is underpinned by subdued profit growth, declining quarterly earnings, and a valuation that reflects a premium relative to book value. Despite a strong return on equity and a debt-free balance sheet, the company’s recent financial results and price performance indicate challenges in sustaining growth momentum.
Conclusion
Concord Biotech’s stock reaching a 52-week low underscores the pressures faced by the company within a competitive Pharmaceuticals & Biotechnology sector. The stock’s current price level and financial indicators provide a comprehensive picture of its recent performance and valuation context as of December 2025.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
